Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05757869 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Study acronym: LIBREXIA-AF
StatusActive, Not Recruiting
PhasePhase 3
Started2023-04-11
View on ClinicalTrials.gov ↗
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

Amendment history 3 changes detected by DataLookout

2026-08-29
Primary completion pushed: 2026-10-31 → 2026-12-08
2026-08-29
Completion pushed: 2026-10-31 → 2026-12-08
2026-04-14
Trial sites expanded: 1041 → 1052 locations
Trial Details
NCT Number NCT05757869
Lead Sponsor Janssen Research & Development, LLC
Collaborators: Bristol-Myers Squibb
Conditions Atrial Fibrillation
Enrollment 20,284 participants
Start Date 2023-04-11
Primary Completion 2026-12-08 (estimated)
Study Completion 2026-12-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-28